"Porfim\u00E8re sodique"@en . "10-452 hours"@en . "87806-31-3"@en . . "Indicated in the treatment of esophageal cancer."@en . "* Renal cl=199.7\u00A0+/- \u00A056.9 mL/min [Healthy subjects receiving a single 300-mg oral dose]"@en . "~90%"@en . "Humans and other mammals"@en . . . "Photofrin II"@en . . "Cellular damage caused by porfimer is a consequence of the propagation of radical reactions. Radical initiation may occur after porfimer absorbs light to form a porphyrin excited state. Spin transfer from porfimer to molecular oxygen may then generate singlet oxygen. Subsequent radical reactions can form superoxide and hydroxyl radicals. Tumor death also occurs through ischemic necrosis secondary to vascular occlusion that appears to be partly mediated by thromboxane A2 release."@en . . "Porfimer"@en . . . "Porfimer sodico"@en . "approved"@en . . " "@en . "Porfimerum natricum"@en . "The purified component of hematoporphyrin derivative, it consists of a mixture of oligomeric porphyrins. It is used in photodynamic therapy (hematoporphyrin photoradiation); to treat malignant lesions with visible light and experimentally as an antiviral agent. It is the first drug to be approved in the use of photodynamic therapy in the United States. [PubChem]"@en . . . . . "investigational"@en . . . . " "@en . . . . . "Dihematoporphyrin ether"@en . . "Porfimer natrium"@en . . . . . . "* 0.49 \u00B1 0.28 L/kg [2 mg/kg dose of porfimer sodium to 4 male cancer patients]"@en . . . . . . . . . . . . "Dihaematoporphyrin Ether"@en .